Last reviewed · How we verify
Placebo to telcagepant capsules
Placebo to telcagepant capsules is a CGRP receptor antagonist Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development for Migraine prevention.
Telcagepant is a calcitonin gene-related peptide (CGRP) receptor antagonist that blocks CGRP signaling to prevent migraine attacks.
Telcagepant is a calcitonin gene-related peptide (CGRP) receptor antagonist that blocks CGRP signaling to prevent migraine attacks. Used for Migraine prevention.
At a glance
| Generic name | Placebo to telcagepant capsules |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | CGRP receptor antagonist |
| Target | CGRP receptor (calcitonin gene-related peptide receptor) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Telcagepant works by antagonizing the calcitonin gene-related peptide receptor, a key mediator in migraine pathophysiology. By blocking CGRP receptor signaling in the trigeminal system and central nervous system, it reduces the neuroinflammatory cascade that leads to migraine headaches. This mechanism addresses the underlying biology of migraine rather than just treating acute symptoms.
Approved indications
- Migraine prevention
Common side effects
- Dizziness
- Nausea
- Fatigue
- Liver enzyme elevation
Key clinical trials
- A Study to Test the Safety and Effectiveness of MK-0974 (Telcagepant) Co-administered With Ibuprofen or Acetaminophen in Patients With Migraines With or Without Aura (MK-0974-046) (PHASE2)
- Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034) (PHASE3)
- A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014) (PHASE1)
- Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011) (PHASE3)
- Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012) (PHASE3)
- Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK-0974 (Telcagepant) in Migraine Patients (0974-026) (PHASE1)
- Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to telcagepant capsules CI brief — competitive landscape report
- Placebo to telcagepant capsules updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Placebo to telcagepant capsules
What is Placebo to telcagepant capsules?
How does Placebo to telcagepant capsules work?
What is Placebo to telcagepant capsules used for?
Who makes Placebo to telcagepant capsules?
What drug class is Placebo to telcagepant capsules in?
What development phase is Placebo to telcagepant capsules in?
What are the side effects of Placebo to telcagepant capsules?
What does Placebo to telcagepant capsules target?
Related
- Drug class: All CGRP receptor antagonist drugs
- Target: All drugs targeting CGRP receptor (calcitonin gene-related peptide receptor)
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Migraine prevention
- Compare: Placebo to telcagepant capsules vs similar drugs
- Pricing: Placebo to telcagepant capsules cost, discount & access